Filana Therapeutics (FLNA) Tax Provisions (2022 - 2025)

Filana Therapeutics has reported Tax Provisions for 3 years, with the latest figure at -$19.1 million in Q4 2025.

• On a quarterly basis, Tax Provisions changed N/A year-over-year to -$19.1 million in Q4 2025; TTM through Jun 2026 was -$19.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $111.9 million, up 15.73% from the prior year.
• Tax Provisions was -$19.1 million for Q4 2025 at Filana Therapeutics, down from $77.3 million in the prior quarter.
• The five-year high for Tax Provisions was $77.3 million in Q4 2023, with the low at -$19.1 million in Q4 2025.
• Average Tax Provisions over 3 years is $37.4 million, with a median of $54.0 million recorded in 2022.
• The largest YoY upside for Tax Provisions was 43.23% in 2023 against a maximum downside of 43.23% in 2023.
• Over 3 years, Tax Provisions stood at $54.0 million in 2022, then surged by 43.23% to $77.3 million in 2023, then slumped by 124.7% to -$19.1 million in 2025.
• The last three Tax Provisions figures came in at -$19.1 million (Q4 2025), $77.3 million (Q4 2023), and $54.0 million (Q4 2022), per Business Quant data.